Skip to content
OpenCapital
Get started

Biogen BIIB TECFIDERA — Total Revenue

Other product segments

TYSABRI
$441.5M+15.7%
SPINRAZA
$374M-11.8%
VUMERITY
$179M+29.0%
AVONEX
$163.2M-2.2%
SKYCLARYS
$150.7M+21.6%
BENEPALI
$122.1M+9.7%
PLEGRIDY
$64.3M+8.1%
ZURZUVAE
$55.4M+100%
IMRALDI
$49.6M+4.6%
QALSODY
$32.5M+110%
FLIXABI
$10.5M-19.8%
BYOOVIZ
$0-100%
FAMPYRA
$0-100%
FUMADERM And ADUHELM
$0-100%
TOFIDENCE
$0-100%

Similar metrics at other companies

Gilead Sciences logo
GILDTecartus — Total revenues
$75M-3.8%
Amgen logo
AMGNTEZSPIRE — Total revenues
$343M+20.4%
Amgen logo
AMGNTEPEZZA — Total revenues
$490M+28.6%
Johnson & Johnson logo
JNJTecvayli — Sales to customers (Note 9)
$202M+33.8%
Johnson & Johnson logo
JNJTremfya — Sales to customers (Note 9)
$1.61B+68.2%
Innoviva, Inc. logo
INVAZEVTERA — Revenue
$438K—

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M—
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.89B+72.3%
Enterprise value$35.07B+57.0%
P/E22.5×+10.4×
P/S3.2×+1.4×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%—
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's tecfidera — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's TECFIDERA — total revenue?
Biogen (BIIB) reported TECFIDERA — total revenue of $109.5M in Q1 2026.
How has Biogen's TECFIDERA — total revenue changed year-over-year?
Biogen's TECFIDERA — total revenue decreased by 46.9% year-over-year, from $206.1M to $109.5M.
What is the long-term trend for Biogen's TECFIDERA — total revenue?
Over 4 years (2021 to 2025), Biogen's TECFIDERA — total revenue has grown at a -23.2% compound annual growth rate (CAGR), from $1.95B to $679.7M.
What does TECFIDERA — total revenue mean?
Represents the total gross sales generated from the Tecfidera product line, net of returns, allowances, and rebates. This metric tracks the commercial performance and market adoption of this specific multiple sclerosis therapy within the company's portfolio.